August 5, 2021
Mitsubishi Tanabe said on August 4 that its spinal cord injury treatment MT-3921 has been granted fast-track designation from the US FDA. MT-3921 is a humanized anti-repulsive guidance molecule A (RGMa) antibody being developed globally for spinal cord injury. It...read more